Mike joined EyeBio as Chemistry, Manufacturing, and Control (CMC) Lead, Drug Development in 2023. In this capacity, Mike is responsible for the development of all CMC related aspects of the pipeline post candidate confirmation.
Bringing over 25 years of experience in the biotechnology industry, with multiple successful IND and MAA/BLA submissions across different biological modalities, Mike is an expert in both CMC and drug development.
Previously, Mike was Head of Analytical Services at Lonza Biologics, VP of Protein Sciences at F-star, and has also worked to support a diverse range of biotechnology companies with Protein Science, CMC, and IND and BLA projects including recombinant proteins, mAbs, Fc fusion proteins, bi-specific antibodies, vaccines, and ATMPs.
Mike received B.Sc. in Biochemistry from Lancaster University.